Sort   by:  
 Page size 
ProteomicsMECOM: A novel player in AR-driven Treatment Resistant Castration-Resistant Prostate Cancer
Reprogramming of the androgen receptor (AR) cistrome is associated with disease progression, and advanced castrate-resistant prostate cancers (CRPC) tend to rely on a reprogrammed/non-canonical AR signaling that is addictive to AR signaling inhibitor (ARSI) resistance. We identified EVI1, an oncogen...
ORGANISM(S): Homo sapiens (Human) 
2026-06-08 | PXD062331 | Pride
Mecom Epigenetics Castration-resistance Drug resistance Parpi Prostate cancers Enzalutamide-resistance Androgen receptor Evi1-mds1 complex Non-canonical ar 
GenomicsEpigenetic Landscape Reveals MECOM As An Endothelial Lineage Regulator
Epigenetic Landscape Reveals MECOM As An Endothelial Lineage Regulator
PRJNA673857 | ENA
ProteomicsA novel microprotein HDSP encoded by HOXA10-HOXA9 triggers progression of gastric cancer through maintaining the stability of MECOM and activating SPINK1-EGFR signaling
The abundance of noncanonical open reading frames present in long noncoding RNAs (lncRNAs) indicates the potential for translational capacity, thereby enabling the generation of multiple functional peptides or proteins. Nevertheless, the existence of peptide or protein products derived from lncRNAs ...
ORGANISM(S): Homo sapiens (Human) 
2024-05-07 | PXD043737 | Pride
Human，gastric cancer，lc-msms 
UnknownMECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia.
Not available
S-EPMC12490727 | biostudies-literature
ProteomicsEffect of BET inhibitor, mivebresib, dactolisib or LCL-161 on protein expressions in AML cells with MECOM rearrangement and high expression of EVI1
Patient-derived AML194 (acute myeloid leukemia with inv3(q21;q26.2)) cells were treated in duplicate with 0 nM or 500 nM of mivebresib, 500 nM of dual PI3K/mTOR inhibitor dactolisib or 1000 nM of IAP antagonist LCL-161 for 24 hours to determine the global protein expression alterations that correlat...
ORGANISM(S): Homo sapiens (Human) 
2026-02-16 | PXD063413 | Pride
Bet inhibitor Mecom Evi1 Mtor Aml 
ProteomicsEffect of SMARCA2/SMARCA4 inhibitor, FHD-286, on protein expression alterations in cultured cell line or patient-derived AML cells with MECOM rearrangement and expression of EVI1
Patient-derived AML191 (acute myeloid leukemia with inv3(q21;q26.2)), -7) cells were treated in duplicate with 100 nM of FHD-286 for 0, 8, 16, 24 and 48 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment ...
ORGANISM(S): Homo sapiens (Human) 
2026-01-23 | PXD059059 | Pride
Mecom Brg1 Evi1 Fhd-286 Aml 
GenomicsCEBPA repression by MECOM blocks differentiation to drive aggressive leukemias [ChIP-Seq]
CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias [ChIP-Seq]
PRJNA1199529 | ENA
UnknownEpigenetic landscape reveals MECOM as an endothelial lineage regulator.
Not available
S-EPMC10130150 | biostudies-literature
GenomicsCEBPA repression by MECOM blocks differentiation to drive aggressive leukemias [ATAC-Seq]
CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias [ATAC-Seq]
PRJNA1199523 | ENA
GenomicsCEBPA repression by MECOM blocks differentiation to drive aggressive leukemias [PRO-Seq]
CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias [PRO-Seq]
PRJNA1199528 | ENA
Sort   by:  
 Page size